Receptor tyrosine kinases and their activation in melanoma.
about
Emerging phytochemicals for prevention of melanoma invasionResistance to BRAF inhibitors: unraveling mechanisms and future treatment optionsAdapt, Recycle, and Move on: Proteostasis and Trafficking Mechanisms in MelanomaCombinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.The MAPK pathway as an apoptosis enhancer in melanoma.Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics.BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.Phosphoproteomic screen identifies potential therapeutic targets in melanoma.The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or LeukemiaCombinatorial Pharmacophore-Based 3D-QSAR Analysis and Virtual Screening of FGFR1 Inhibitors.Narrowing the knowledge gaps for melanomamiR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma.Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review).Genetics of melanoma progression: the rise and fall of cell senescence.Crosstalk signaling in targeted melanoma therapy.The WNT-less wonder: WNT-independent β-catenin signaling.Genomewide RNAi screen identifies protein kinase Cb and new members of mitogen-activated protein kinase pathway as regulators of melanoma cell growth and metastasis.Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells.Uncarboxylated Osteocalcin Induces Antitumor Immunity against Mouse Melanoma Cell Growth.SOX10-MITF pathway activity in melanoma cells.Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines.Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma.Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment.
P2860
Q27023283-45DE689C-5177-45D8-866C-CF910957EAB8Q27023596-3605936C-21B5-47FA-8F3A-79EC478FB297Q28069018-BCE62813-4129-4B6D-92CF-CEB55542D870Q30277902-A928816A-CF3D-494C-850E-7A5413737AC0Q34104135-989BF92D-C290-4339-A9B5-42A92E340754Q34273411-A1E106D0-E80A-4E68-B17C-24591F7E66F1Q34374407-4A1D0EC4-0781-4DFB-A1CC-01055287CD42Q35053505-BED04560-DCD7-4DDE-AE02-90BA4E07D7BAQ35597799-95675149-5729-4F46-AA66-E8F0F7E1EE50Q35666005-2D7737D6-4930-4826-B98F-EA69056F0075Q35814029-E91E1C57-1C99-44D3-8086-7580BAD377DEQ37984547-954501AC-D905-4D37-8298-676665DB1E46Q38138933-A66C34FB-2933-4490-9A0E-A09173AE6452Q38219616-D9D2C768-56BA-48BF-AEBB-56BE2BC73CB1Q38589518-DD8E298F-BC67-4424-813D-C9A960F4BB91Q38757522-D62256E3-14A2-44D7-8525-1E64263B284CQ38867422-8E456E74-D219-4DBC-BAAD-BFAAA6822F84Q39035993-E0DB5CEB-E73E-49AA-87A4-673C9CC36010Q39325740-5FAC9C14-5831-495D-9CE7-3E3CF3E300D2Q39379086-D87C7275-1B08-4813-9DA7-97843B2FE961Q41243255-580DAFFC-B04E-47A8-BBAC-44C81E1B8BE5Q47104368-1D0F9EE2-1A3F-437C-870F-AEC7A27FBA69Q53688956-74B91DA5-6460-47F6-A656-B68AF96FA190Q54171446-BC5FB139-AE6F-41E9-86C1-9D5635A86101Q54409415-AB4EEB22-9897-409A-911F-3922D8A91783Q55352057-E53AB69A-1276-45B8-934C-DC401C4EEAE4
P2860
Receptor tyrosine kinases and their activation in melanoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Receptor tyrosine kinases and their activation in melanoma.
@en
Receptor tyrosine kinases and their activation in melanoma.
@nl
type
label
Receptor tyrosine kinases and their activation in melanoma.
@en
Receptor tyrosine kinases and their activation in melanoma.
@nl
prefLabel
Receptor tyrosine kinases and their activation in melanoma.
@en
Receptor tyrosine kinases and their activation in melanoma.
@nl
P2093
P2860
P1476
Receptor tyrosine kinases and their activation in melanoma
@en
P2093
David J Easty
Dearbhaile O'Donnell
Kenneth J O'Byrne
P2860
P304
P356
10.1111/J.1755-148X.2011.00836.X
P577
2011-03-03T00:00:00Z